News | February 06, 2026
Aarti Drugs reports strong Q3 FY26 performance, PAT surges 58% YoY
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
Subscribe To Our Newsletter & Stay Updated
